Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 05/27 10:00:26 pm
113.06 USD   +0.14%
05/27 JOHNSON & JOHNS : SIMPONI® Receives CHMP Positive Opinion For Treatm..
05/27 JOHNSON & JOHNS : Remember these? Pinto, Tylenol and other infamous ..
05/27 JOHNSON & JOHNS : Canadian class action claims Johnson's baby powder..
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : FDA : J&J Unit Recalls Potentially Flammable Bone Putty

share with twitter share with LinkedIn share with facebook
share via e-mail
08/22/2012 | 12:13am CEST
   By Ben Fox Rubin 

The Food and Drug Administration said Johnson & Johnson (JNJ) unit Synthes last month initiated a recall on certain lots of bone putty, saying the medical product could catch fire during surgery.

The FDA gave the recall a Class I designation, its most serious type of recall.

The regulator said Synthes in early July issued a medical device recall letter, asking medical facilities to examine their inventories and immediately stop using specific lots of the putty. The product, called a hemostatic bone putty, is used to stop bone bleeding by creating a physical barrier along the edges of bones that have been damaged by trauma or cut during surgery.

The FDA said the putty could ignite under some conditions if contacted with certain surgical equipment.

The lots recalled were manufactured between July 6, 2011, and Dec. 14, 2011, and were distributed from Dec. 22, 2011, to June 25, 2012.

J&J in June completed its $19.7 billion purchase of medical-device maker Synthes. The health-care giant has worked to tackle a range of problem products, such as the bottles of children's Tylenol and other popular over-the-counter medicines, as well as some contact lenses and certain hip implants, that the company recalled due to manufacturing problems.

The company's shares closed Tuesday at $67.78 and were up 15 cents after hours. The stock is up 3.4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
React to this article
Latest news on JOHNSON & JOHNSON
05/27 JOHNSON & JOHNSON : SIMPONI® Receives CHMP Positive Opinion For Treatment Of Pol..
05/27 JOHNSON & JOHNSON : Remember these? Pinto, Tylenol and other infamous recalls
05/27 JOHNSON & JOHNSON : Canadian class action claims Johnson's baby powder failed to..
05/27 MYOB : Australia’s Best Employers Revealed
05/26 JOHNSON & JOHNSON : Pharma company developing cancer drug moving to Houston
05/25 JOHNSON & JOHNSON : to Participate in the Goldman Sachs 37th Annual Global Healt..
05/25 AGS : Pelvic mesh implants caused dire complications
05/25DJJOHNSON & JOHNSON : Washington, California Sue Johnson & Johnson Over Vaginal Me..
05/24 JOHNSON & JOHNSON : Healthcare Sector Stock Business Review
05/24 JOHNSON & JOHNSON : U.S. FDA Expands Indication of INVOKAMET® (canagliflozin/met..
News chart
Full-screen chart
Income Statement Evolution
More Financials